{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:09:20Z","timestamp":1764133760442,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bneo.2025.100094","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T19:05:18Z","timestamp":1741633518000},"page":"100094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant"],"prefix":"10.1016","volume":"2","author":[{"given":"Brian","family":"Cuzzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maegan","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-7520","authenticated-orcid":false,"given":"Saagar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-8447","authenticated-orcid":false,"given":"Hua-Jay","family":"Cherng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-1500","authenticated-orcid":false,"given":"Evelyn","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8785-8162","authenticated-orcid":false,"given":"Amy","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5283-7789","authenticated-orcid":false,"given":"Yuxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-048X","authenticated-orcid":false,"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-2469","authenticated-orcid":false,"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bneo.2025.100094_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.18065","article-title":"Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres","volume":"197","author":"Santarsieri","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100094_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100094_bib4","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1182\/blood-2023-187969","article-title":"Infectious complications and mortality in post-transplant lymphoproliferative disorder following solid organ transplantation: experiences of 10 years in a single center","volume":"142","author":"Orland","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100094_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J of Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100094_bib6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.bneo.2025.100094_bib7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100094_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/HS9.0000000000000640","article-title":"Clinicopathologic characteristics, treatment, and outcomes of post-transplant lymphoproliferative disorders: a single-institution experience using 2017 WHO diagnostic criteria","volume":"5","author":"King","year":"2021","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.bneo.2025.100094_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100094_bib10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100094_bib11","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","article-title":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","volume":"36","author":"Zimmermann","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2025.100094_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.2024023847","article-title":"Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 tidal trial","volume":"144","author":"Chaganti","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100094_bib13","doi-asserted-by":"crossref","first-page":"1848068","DOI":"10.1080\/2162402X.2020.1848068","article-title":"Cancer risks in solid organ transplant recipients: results from a comprehensive analysis of 72 cohort studies","volume":"9","author":"Huo","year":"2020","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.bneo.2025.100094_bib14","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2025.100094_bib15","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional epoch chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2025.100094_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.bneo.2025.100094_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100094_bib18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100094_bib19","article-title":"Epstein-Barr virus\u2013positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management.","volume":"2","author":"Nijland","year":"2015","journal-title":"Transplant Direct"},{"issue":"5","key":"10.1016\/j.bneo.2025.100094_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients \u2013 BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100094_bib21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ajt.12196","article-title":"Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"13","author":"Morscio","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bneo.2025.100094_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fonc.2020.00506","article-title":"Biological difference between Epstein\u2013Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact","volume":"10","author":"Ferla","year":"2020","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100094_bib23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/modpathol.2016.130","article-title":"EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations","volume":"29","author":"Courville","year":"2016","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100094_bib24","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.bneo.2025.100094_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1432-2277.2006.00284.x","article-title":"Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab","volume":"19","author":"Svoboda","year":"2006","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.bneo.2025.100094_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/2040620711412417","article-title":"Therapeutic options in post-transplant lymphoproliferative disorders","volume":"2","author":"Zimmermann","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100094_bib27","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100094_bib28","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/j.1600-6143.2005.01098.x","article-title":"Effect of anti-cd 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)","volume":"5","author":"Oertel","year":"2005","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.bneo.2025.100094_bib29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"Gonzalez-Barca","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bneo.2025.100094_bib30","article-title":"Post-transplant lymphoproliferative disorder (PTLD) in the US population with demographics, treatment characteristics, and survival analysis","volume":"15","author":"Ullah","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.bneo.2025.100094_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-017-0087-0","article-title":"Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients","volume":"6","author":"Bishnoi","year":"2017","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100094_bib32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/cancers13040899","article-title":"Analysis of post-transplant lymphoproliferative disorder (PTLD) outcomes with Epstein\u2013Barr virus (EBV) assessments\u2014a single tertiary referral center experience and review of literature","volume":"13","author":"Lau","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.bneo.2025.100094_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1155\/2015\/517359","article-title":"Post-transplant lymphoproliferative disorder in liver transplant recipients: characteristics, management and outcome from a single-centre experience with >1000 liver transplantations","volume":"29","author":"Mumtaz","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100094_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.16304","article-title":"Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder","volume":"189","author":"Jain","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100094_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12782","article-title":"First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study","volume":"98","author":"Mart\u00ednez-Calle","year":"2016","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100094_bib36","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1097\/TP.0000000000003183","article-title":"Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant","volume":"104","author":"Burns","year":"2020","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bneo.2025.100094_bib37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International Prognostic Index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:59:17Z","timestamp":1762657157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2950328025000299"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100094","relation":{},"ISSN":["2950-3280"],"issn-type":[{"type":"print","value":"2950-3280"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100094"}}